bullish
Oneness Biotech (4743 TT): Positive Clinical Trial Progress Is Pushing Stock Prices to Higher Highs
187 Views30 Aug 2022 16:23
SUMMARY
- Oneness Biotech (4743 TT) is showing steady progress in its R&D pipeline. The company submitted IND application to FDA for phase 1 trial of SNS812 for the treatment of COVID-19.
- SNS812 is a first-in-class broad-spectrum siRNA-based new drug against SARS-CoV-2 variants covering 99.8% of current variants and shown picomolar inhibition of dominant ones, including Alpha, Delta, Gamma, Epsilon, and Omicron.
- The health authorities in Singapore, Malaysia, the Philippines, and Vietnam have accepted the NDA application of Fespixon, which has been commercialized in Taiwan last year for diabetes foot ulcer.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
x